EMvision Medical Devices Ltd
EMVision Medical Devices Limited is an Australian medical device company.
The business
EMVision Medical Devices Limited is an Australian medical device company. The Company is focused on the development and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. The Company’s primary focus is portable and non-invasive brain scanners, including a bedside device (emu) and an ultra-light weight pre-hospital device (First Responder). Its first indication is in stroke care. Its product pipeline includes portable and non-invasive brain scanners, including a bedside device (emu) and a light weight first responder pre-hospital device. Its First Responder Brain Scanner device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location. The emu Brain Scanner device detects clinically significant changes, at the bedside, when time matters.
Small Caps Research
No research on EMvision Medical Devices Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise EMV based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
EMVision Medical Devices Prepares Study to Support Remote Use of emu Bedside Brain Scanner
EMVision moves to remote stroke care with emu bedside scanner; regional study protocol set, telehealth-enabled diagnosis could shift rural care (ASX: EMV).
EMVision Making Strong Progress with emu and First Responder Brain Scanners
EMVision advances emu brain scanner validation; recruitment milestones hit as ischaemia endpoint eyed to bolster FDA De Novo clearance and value.
EMVision Medical Devices De-Risks Rural Stroke Use Cases with Aeromedical Study
EMVision de-risks rural stroke use with aeromedical feasibility study; First Responder Brain Scanner unaffected by flight, cash reserves of $18.4m.
EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection
EMVision expands FDA De Novo trial to include acute ischaemia detection for its emu device, widening indications as recruitment hits 125 and cash AUD 18.4m.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.